期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 18, 期 -, 页码 702-712出版社
CELL PRESS
DOI: 10.1016/j.omtm.2020.07.013
关键词
-
资金
- National Key R&D Program of China [2016YFC1201000]
- National Science Foundation of China [31670941, 31870916]
Dengue virus (DENV) infection is a major global public health concern, and there is no effective vaccine for it. In this study, we describe the design and characterization of three nucleotide-modified mRNA vaccines (prME-mRNA, E80-mRNA, and NS1-mRNA) for DENV-2. Our results showed that vaccination with E80-mRNA alone or a combination of E80-mRNA and NS1-mRNA can induce high levels of neutralizing antibodies and antigen-specific T cell responses; furthermore, these vaccines confer complete protection against DENV-2 challenge in immunocompetent mice. These data provide foundations for further development of a tetravalent DENV vaccine based on nucleotide-modified mRNA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据